State of New Jersey Common Pension Fund D Has $2.53 Million Stake in Elanco Animal Health Incorporated $ELAN

State of New Jersey Common Pension Fund D trimmed its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 4.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 177,037 shares of the company’s stock after selling 7,497 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Elanco Animal Health were worth $2,528,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Allworth Financial LP grew its position in Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock valued at $25,000 after purchasing an additional 2,090 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in Elanco Animal Health by 261.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company’s stock valued at $58,000 after purchasing an additional 2,922 shares in the last quarter. Wealthquest Corp bought a new position in Elanco Animal Health in the first quarter valued at $56,000. Parallel Advisors LLC grew its position in Elanco Animal Health by 66.6% in the second quarter. Parallel Advisors LLC now owns 6,432 shares of the company’s stock valued at $92,000 after purchasing an additional 2,572 shares in the last quarter. Finally, Covestor Ltd grew its position in Elanco Animal Health by 510.9% in the first quarter. Covestor Ltd now owns 7,087 shares of the company’s stock valued at $74,000 after purchasing an additional 5,927 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on ELAN. Stifel Nicolaus raised their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Leerink Partners raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price for the company in a research report on Thursday, July 17th. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Elanco Animal Health in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $18.00 to $24.00 in a research report on Tuesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $22.13 on Wednesday. The firm has a 50-day moving average of $19.50 and a 200-day moving average of $15.45. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $22.45. The company has a market cap of $10.99 billion, a PE ratio of 25.73, a price-to-earnings-growth ratio of 4.09 and a beta of 1.65. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter last year, the firm posted $0.30 EPS. The company’s quarterly revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.